23andMe, a genetic testing company, is facing bankruptcy proceedings that have raised concerns about employee layoffs and the status of customer genetic data. According to a WARN notification, the company could lay off up to 223 employees as it navigates a sale process, which may involve selling off assets individually rather than as a whole business. This uncertainty follows previous staff reductions and the resignation of CEO Anne Wojcicki. Employees have expressed anxiety about the handling of their genetic information by future buyers.
The genetic testing company is in the throes of bankruptcy litigation, expecting multiple bids for the company's DNA data bank and other assets.
23andMe warned its employees of potential layoffs, with up to 223 positions possibly affected as they undergo the sale process amid financial upheaval.
Collection
[
|
...
]